Please assess the completion status of the following clinical trial:

Trial Title: Study of Brain Function in Women With Insulin Resistant Polycystic Ovary Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Insulin-resistant PCOS (Arm: PCOS Affected Women)~* Irregular menstrual cycle (Arm: PCOS Affected Women)~* Hyperandrogenism (Arm: PCOS Affected Women)~* Regular menstrual cycles (Arm: Normal Controls)~* Normal hormonal levels (Arm: Normal Controls)~* Lack of hirsutism (Arm: Normal Controls)~* Acne-free (Arm: Normal Controls)~* Candidates are BMI-matched and screened for insulin resistance prior to inclusion. (Arm: Normal Controls)~Exclusion Criteria:~* Left handedness~* Acute medical illness~* Uncorrected thyroid disease~* Diabetes renal~* Cardiac or pulmonary insufficiency~* Active liver disease~* Neurological disease~* Current psychiatric illness~* Claustrophobia~* Contraindications to MRI~* Smoking~* Use of hormones~* Centrally acting or insulin sensitizing mediations~* Allergy to any opioid medication~* Substance abuse~* Pregnancy~* BMI \>35.

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Normal Controls (Type: NO_INTERVENTION): Control subjects will have 5 visits (screening, oral glucose tolerance test (OGTT), neuropsychological testing, functional magnetic resonance imaging (fMRI) and positron emission tomography (PET) as they will receive no treatment and will not have repeat studies. The baseline values obtained from the control subjects will be compared to the baseline values acquired from the PCOS affected subjects.
- PCOS Affected Women-Metformin Treatment (Type: EXPERIMENTAL): Subjects with Polycystic Ovary Syndrome (PCOS) will be scheduled for 9 visits total: following the screening visit they will go through OGTT, neuro-psychological testing, fMRI and PET scan before and after 4 months of metformin use: 500mg tablets once daily with breakfast for 1 week, then increased to one tablet twice daily with breakfast \& lunch for 1 week, then increased to one tablet three times daily with breakfast, lunch \& dinner.

Based on this trial design, predict the completion outcome and termination type (if applicable).